Eunjae Sung
Primary Care · Gardena, CANPI 1235594185
Payments from drug & device makers
Across 133 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$861
- Lilly USA, LLC$455
- AbbVie$361
- AstraZeneca$256
- Novo Nordisk$105
- Exact Sciences$91
- plus $464 from 12 others
What the payments were for
- Food & beverage$2,593100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 53 | $861 |
| Lilly USA, LLC | 21 | $455 |
| AbbVie | 19 | $361 |
| AstraZeneca | 12 | $256 |
| Novo Nordisk | 4 | $105 |
| Exact Sciences | 4 | $91 |
| Scilex Pharmaceuticals Inc. | 4 | $87 |
| Kowa Pharmaceuticals America, Inc. | 3 | $64 |
| Bayer | 2 | $54 |
| Pfizer | 2 | $53 |
| Boehringer Ingelheim | 2 | $52 |
| Carestream Dental, LLC | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| GSK | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Alk-abello, Inc | 1 | $17 |
How this compares
$2,593 in reported general payments places this provider in the 85th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 99 | $79,474 |
| CreonLipase/Protease/Amylase | 80 | $67,106 |
| JanuviaSitagliptin Phosphate | 68 | $66,441 |
| ProliaDenosumab | 34 | $56,965 |
| FarxigaDapagliflozin Propanediol | 63 | $50,693 |
| TrulicityDulaglutide | 50 | $47,573 |
| VascepaIcosapent Ethyl | 129 | $34,669 |
| TradjentaLinagliptin | 44 | $22,376 |
| LinzessLinaclotide | 34 | $19,875 |
| XareltoRivaroxaban | 30 | $17,561 |
| MyrbetriqMirabegron | 17 | $9,578 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $8,944 |
| Icosapent Ethyl | 45 | $8,449 |
| Lidocaine | 48 | $5,472 |
| Memantine Hcl ErMemantine Hcl | 23 | $5,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $52 | $101,850143 claims |
| AbbVieCreon, Linzess, Namzaric | $361 | $95,925126 claims |
| AmgenProlia | $861 | $56,96534 claims |
| AstraZenecaFarxiga | $256 | $50,69363 claims |
| Lilly USA, LLCTrulicity | $455 | $47,57350 claims |
| Johnson & JohnsonXarelto | $20 | $17,56130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 706 primary care providers in California.
Other primary care in Gardena
- Flora LimGardena$3K
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Joann BallPalm Desert$56K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.